z-logo
open-access-imgOpen Access
Serial Measurement of Sister Chromatid Exchanges in the Peripheral Lymphocytes of Patients with Lung Cancer Receiving Chemotherapy in Relation to Bone Marrow Toxicity
Author(s) -
Shinkai Tetsu,
Saijo Nagahiro,
Eguchi Kenji,
Sasaki Yasutsuna,
Tamura Tomohide,
Fujiwara Yasuhiro,
Kojima Akira,
Nakagawa Kazuhiko,
Minato Kouichi,
Nakajima Takashi,
Suemasu Keiichi
Publication year - 1989
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1989.tb01715.x
Subject(s) - vindesine , leukopenia , etoposide , chemotherapy , bone marrow , cyclophosphamide , medicine , mitomycin c , lung cancer , cisplatin , vincristine , toxicity , sister chromatid exchange , gastroenterology , oncology , biology , surgery , biochemistry , in vitro
The frequencies of sister chromatid exchanges (SCE) in the peripheral lymphocytes of patients with lung cancer before and after initial chemotherapy were serially measured and the correlation between SCE frequencies and bone marrow toxicity was evaluated. The addition of mitomycin C to vindesine plus cisplatin increased SCE frequencies significantly in patients with non‐small cell lung cancer. A significant increase in frequencies of SCE was observed in patients treated with cyclophosphamide plus adriamycin plus vincristine as compared with those treated with cisplatin plus etoposide in small cell lung cancer. A significant inverse correlation was observed between SCE frequencies in the peripheral lymphocytes 7 days after treatment ( x ) and the nadir value/pretreatment value of platelets ( y )( r = ‐0.685, P = 0.0007, y = 0.842–0.022 x ). The relation between SCE frequency and leukopenia showed the same trend as thrombocytopenia, but the correlation was not statistically significant ( r = ‐ 0.444, P = 0.057). SCE assay may have potential clinical use for the prediction of chemotherapyinduced thrombocytopenia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here